You can narrow down the results using the filters
-
Semaglutide for post-liver transplant metabolic dysfunction-associated steatotic liver disease (MASLD)
Expand descriptionMetabolic (dysfunction)-associated steatotic liver disease (MASLD) is increasing in prevalence worldwide and is becoming one of the most common indications of liver transplant. Obesity rates are also rising globally and is a common comorbidity in liver transplant recipients. As medical management improves for liver transplant recipients, many achieve long-term survival well beyond 20 years. Obesity-related complications such as cardiovascular disease and cancer are now responsible for an ever-increasing proportion of post-transplant deaths. Development of de novo obesity and metabolic complications including hepatic steatosis is becoming an increasing medical issue following liver transplant, however there is currently no proven intervention to successfully mitigate post-liver transplant hepatic steatosis and obesity, despite aggressive nutritional interventions. The purpose of this study is to identify patients with post-transplant hepatic steatosis and to intervene with pharmacotherapy in the form of subcutaneous semaglutide. We aim to not only reduce hepatic steatosis but also improve the metabolic and cardiovascular risk profile and thereby reduce the incidence of related health conditions that are frequently observed in this population. This study will be a double-blinded randomized controlled trial in post-liver transplant patients with obesity and/or metabolic risk factors. We will study the impact of subcutaneous semaglutide in reducing hepatic steatosis and the impact on body composition, metabolic and cardiovascular disease outcomes.
-
The Coronary Artery Calcium Scoring in Women with Novel Cardiovascular Risk Factors Trial (CAC-Women Trial)
Expand descriptionCardiovascular disease is the number one killer of Australian women. Yet CVD is preventable with early initiation of the right lifestyle and medical interventions. Current primary prevention relies on 'traditional' risk prediction tools. But almost all women under 65 are categorised as low risk, the vast majority of women who have coronary events are not identified, and novel, female-specific risk factors (e.g pre eclampsia, hypertensive disorders of pregnancy, gestational diabetes or premature menopause) are not considered. On top of this, women receive less primary prevention medical therapy, compared to men. These issues are even more pronounced in Aboriginal and Torres Strait Islander women (hereafter respectfully referred to as Aboriginal women). who have a larger burden of female-specific risk factors, and are even less likely to receive appropriate primary prevention. The CAC-Women's Trial aims to use a calcium score, measured via a simple, quick and widely available CT scan, to prompt lifestyle changes and medication use in women who are low-intermediate risk but have female-specific, risk-enhancing factors. in a randomised controlled trial (RCT) will evaluate the overall potential, feasibility and acceptability of a CAC-guided approach to primary prevention of CVD in women, and its impact on cardiovascular risk factor control. The CAC-WOMEN Trial will be a multi-site, randomised controlled trial assessing the effectiveness of a CAC-guided primary prevention intervention on cardiovascular risk factor control and healthy lifestyle adherence compared to usual care. The study aims to recruit 522 patients. Asymptomatic women without CVD aged 40-65 years (35-65 years for Aboriginal and Torres Strait Islander women) will be recruited from the community. Women will undergo blinded CT calcium scoring followed by 1:1 randomisation to intervention (CAC-guided care) or control (standard care). In the intervention group, women undergo a risk factor counselling session. This is performed by the study nurse/coordinator (and/or Aboriginal healthcare worker, where appropriate) with a private, one-on-one, CVD risk factor counselling session. The Study nurse/coordinator will provide printed and electronic information containing standardised recommendations consistent with current guidelines, on how to improve CVD risk profiles. The risk factor counselling session will be aided by the use of the CT-CAC result. Patients will receive a follow up telephone call by the study nurse at 1, 3 months, to monitor risk factor modification. In the control group women remain under the care of their primary care physician and are blinded to the CAC result for the 6month period. The participant is provided with a letter detailing the results of the baseline examination and pathology and are encouraged to see their GP for a discussion of risk factor treatment in accordance with standard care. All participants will be sent electronic survey follow up at 12m.
-
Changes in corneal epithelial irregularity following treatment with artificial tears in a symptomatic dry eye population
Expand descriptionThe research study aims to evaluate the effect of two different commercially available eye drops on the outermost layer (epithelium) of the cornea (clear, front surface of the eye), compared to saline, in subjects with dry eye. The corneal epithelium is more irregular in subjects with dry eye compared to non-dry eye populations. Therefore, this study will investigate whether the study eye drops improve corneal epithelial irregularity and how quickly this occurs following treatment.. Participants will be randomly allocated (like flipping a coin) to the eye drops to be used in this study four times daily. Assessments will be conducted 48 hours, 2 weeks and 4 weeks after the study eye drops are dispensed. Subjective comfort will also be measured before and at each follow-up visit using questionnaires. The primary timepoint is 2 weeks, but outcomes up to 4 weeks after starting treatment, including the 48 hour timepoint, will be analysed.
-
Acquire versus ViziShot needles in Endobronchial Ultrasound Guided Lymph Node Aspiration
Expand descriptionThis study is aiming to determine whether one of two needles (that are approved by the Therapeutics and Goods Administration) is better than the other for taking samples from mediastinal (chest) lymph nodes for the diagnosis of lung cancers. Who is it for? You may be eligible for this study if you are aged 18 or older and you have been referred by your doctor to undergo a chest lymph node biopsy procedure known as Transbronchial Node Aspiration by Endoscopic Ultrasound. Participants may have a known cancer diagnosis or will be undergoing this procedure to determine a final diagnosis such as, but not limited to, lung cancer, sarcoidosis or tuberculosis. Study details Participants who choose to enrol in this study will be randomly allocated by chance (similar to flipping a coin), to undergo a biopsy by one needle (Acquire), or the other (ViziShot). The biopsy procedure will involve giving anaesthetics then examining airways using a camera passed via vocal cords. Both procedures will be the same, the only difference will be which needle is used. 7- 10 days after the procedure, a member of the research team will phone all participants to check if they have experienced any side effects potentially related to the procedure, including going to the emergency department. It is hoped this research will determine whether one needle is superior to the other, and this may then improve current practice by reducing the number of biopsies needed.
-
Reconnecting After Self-Harm. A trial of a text-message based intervention after self-harm.
Expand descriptionSuicide is the leading cause of death for young people in Australia and hospital treated self-harm is the strongest risk factor for subsequent suicide. Brief contact interventions (BCI) after patients have been discharged have been shown to reduce repeat self-harm. RAFT is an SMS-based BCI that links patients with self-guided therapeutic content. This study will recruit individuals who have recently attended a hospital or emergency department for self-harm. Participants will be assigned to an intervention arm or a treatment-as-usual (TAU) control group. Participants assigned to the intervention arm will receive supportive text messages over 12 months. Adopting a 2x2 factorial design, half the participants assigned to the intervention arm will receive access to the self-guided therapeutic content. Additionally, half the participants assigned to the intervention arm will have the option to nominate a support person to receive information about self-harm and suicide. RAFT is aimed at reducing suicidal ideation and self-harm. This trial will assess whether RAFT is effective compared to treatment as usual, with exploration of the most effective combination of RAFT features. It is hypothesised that participants in the intervention arm will demonstrate greater reductions in suicidal ideation and the event rate of repeat self-harm relative to the control group. Self-report data will be collected remotely via online questionnaires at baseline, 5 weeks, 6 months and 12 months.
-
Development of a codesigned online Healthy Eating Lifestyle Program (HELP) for adults at risk of Posttraumatic Stress Disorder (PTSD): A pilot feasibility study
Expand descriptionPost-Traumatic Stress Disorder (PTSD) is a debilitating and costly condition. Conventional treatments are insufficient and fail to adequately address comorbid conditions such as coronary heart disease and diabetes. Dietary intervention is a well-established approach in the treatment of physical conditions whereas building evidence suggests improving diet quality may address factors that are maintaining and exacerbating PTSD. However, current research in dietary improvement programs for those at risk of PTSD is limited in quantity and quality. We aim to develop and assess the acceptability, engagement and feasibility of a codesigned digital dietary improvement program for those at risk of current PTSD. We will use data collected from a previous study that adapted the My Food and Mood app for adults at risk of PTSD, This information will be used to inform an initial prototype for the Healthy Eating Lifestyle Program (HELP) app. We will pilot HELP with 300 adults at risk of current PTSD. HELP prototypes will be iteratively co-developed with cohorts of 100 participants, based on data analytics and consumer follow up surveys. Changes to PTSD symptoms and diet quality will be also be assessed. This study targets the co-development and optimisation of a digital program targeting diet quality improvement for those at risk of PTSD. Given the relatively high prevalence of PTSD and its enormous individual and societal costs, the online self-help approach could provide a pragmatic and effective adjunct treatment strategy. Outcomes of the project will inform funding applications for a large online RCT to establish the comparative efficacy of dietary interventions for PTSD populations.
-
Tell Your Story: Can an Online Intervention Reduce Stigma and Increase Help-Seeking in Refugee Men and Women?
Expand descriptionThe primary objective of this project is to evaluate the effectiveness of the "Tell Your Story" (TYS) intervention for male and female Arabic-speaking refugees by conducting a randomized controlled trial (RCT). It is hypothesized that participants in the TYS condition will show reduced self-stigma and increased help-seeking relative to a waitlist control group. The secondary aim of this project is to investigate the psychological mechanisms underpinning changes in self-stigma and help-seeking. It is hypothesized that TYS increases help-seeking by decreasing negative stigma related beliefs about help-seeking and by reducing self-stigma via psychological mechanisms (future self-efficacy, self-esteem and help-seeking beliefs).
-
The effect of self-monitoring urate concentrations on adherence to allopurinol in people with gout
Expand descriptionGout has effective, safe and readily available therapies. Yet it continues to be sub-optimally managed in the community. This is due to poor adherence to medication taking. We want to examine the relationship between self-monitoring of urate and urate-lowering medication taking behaviour. We hypothesise that self-monitoring of urate concentrations enhances adherence to urate-lowering medicines. That is, patient measuring their urate and seeing the results will encourage them to take medications as prescribed. We are conducting a proof-of-concept study with 30 people with gout. They are provided with the point-of-care uric acid monitoring meter, the HumaSens2.0plus, for self-monitoring throughout the year. Adherence to medication (MEMS), gout flare occurrence, and urate will monitor throughout the year.
-
Feasibility of Opioid Injectable Treatment
Expand descriptionSupervised Injectable Opioid Treatment (SIOT) is an evidence-based treatment for dependent opioid injectors who have not responded to conventional, oral treatment. This project will implement SIOT as an adjunct to oral methadone and explore whether benefits observed during injectable treatment are sustained after transfer to standard methadone treatment. The 2-year, open-label non-controlled study will be located in a methadone clinic. We will recruit 20-30 long-term injectors of street opioids, prescribe a combination of parenteral hydromorphone and oral methadone, then around 18 months gradually transfer to oral methadone only. The project will provide data to assess the acceptability (to staff and participants), safety, outcomes, and direct costs of SIOT. We will monitor non-prescribed drug use, health, psychological state and quality of life before, during, and after ceasing injectable treatment by performing qualitative interviews with participants, staff and policy makers.
-
To determine whether use of Technetium99m-labelled PSMA improves the sensitivity for detection and aids intra-operative localisation of lymph node metastases in men with intermediate or high-risk localised prostate cancer undergoing robotic-assisted radical prostatectomy.
Expand descriptionThe purpose of this study is to determine whether it is feasible and safe to use Technetium99m-labelled PSMA as a tracer during prostate removal surgery (or a 'radical prostatectomy') for men with prostate cancer. Who is it for? You may be eligible for this study if you are an adult male, who has been diagnosed with prostate cancer and is scheduled to receive a radical prostatectomy. Study details All participants will be asked to come into the hospital around 3-4pm the day before the surgery to receive an injection of the tracer and a scan. Once they have received the tracer, they will be observed for a while before going home. All participants will then proceed with the surgery as planned the next day. It is hoped that this study will be able to determine whether using Technetium99m-labelled PSMA as a tracer during radical prostatectomy is safe and results in better detection of any cancer that may have spread. Follow-up visits To determine the outcome of treatment, the participant will be asked to complete the self-reporting Expanded Prostate Cancer Index Composite (EPIC) survey. The EPIC survey has been extensively used to report on the physical, emotional and psychological outcomes of prostate cancer. The questionnaires will be completed at baseline (prior to surgery), at 6 weeks, 3 months, 6 months, 1 year and then yearly for a minimum of 3-5 years